Login to Your Account

Oscient Encouraged Despite Missed Endpoint In Phase II

By Kim Coghill

Thursday, August 12, 2004
While Oscient Pharmaceuticals Corp. missed its primary endpoint in a Phase II trial of Ramoplanin for the treatment of Clostridium difficile-associated diarrhea, the firm believes the trial's preliminary data are encouraging, and hopes to move into Phase III studies by the end of the year. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription